亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

ALXAN

总结
8-Etinylxanthines: potent dual-target-directed adenosine receptor antagonists with a beneficial neuroprotective function in Parkinson’s and Alzheimer’s disease.
技术优势
New potent dual- and triple-target drugs for the treatment of PD and AD
Multi-target drug with improved compliance, less side effects, reduced toxicity
Significant advantages over combination therapy: more predictable pharmacology, reduced drug-drug interactions, less complex pharmacokinetics
技术应用
these observations position tricyclic xanthine derivatives as ideal candidates for the treatment of neurodegenerative diseases such as PD and AD, but might also be suitable for the treatment of depression, addiction and restless legs syndrome.
详细技术说明
This invention provides newly designed tricyclic xanthine derivatives which allow overcoming this problem. A variety of 69 derivatives were prepared and evaluated in radioligand binding studies at adenosine receptors and for their ability to inhibit monoamine oxidases. Potent dual-target-directed A1/A2A adenosine receptor antagonists were identified. Several compounds even showed triple-target inhibition.
合作类型
Licensing
申请日期
28/06/2011 00:00:00
申请号码
EP20070856895 20071219
分类

- international:
A61K31/495; A61P25/00; C07D473/04; C07D473/06
- cooperative:
C07D473/04; C07D473/06
其他
Patent application
ID号码
1613
国家/地区
德国

欲了解更多信息,请点击 这里
移动设备